Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-28 20:32:03 - browse：55678

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： American woman, child freed after being kidnapped in Haiti last month

entertainment

focus

WSS

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Risky weight loss products often used by teens globally, per study

Why failed clinical trials don’t always spell doom for a new drug

In same hospitals, Black patients receive fewer opioids than white patients

DeSantis can now import cheaper drugs. But will Biden get credit?

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

hotspot

Wikipedia

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

American woman, child freed after being kidnapped in Haiti last month

Novavax promises a turnaround & Lilly roils the obesity market

Designating disabled people as health disparity population is crucial

Activists slam private health insurers over coverage restrictions

JPM 2024: Verve Therapeutics looks to mainstream genome editing

What does generative AI mean for health care? We asked experts

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Medical records are filled with copy

In same hospitals, Black patients receive fewer opioids than white patients

focus

GSK to buy asthma

Emergent cuts jobs, executive role in business shake

New Medicare drug pricing powers could soon be upended in court

The best solution to the drug shortages problem

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

South Korea throws huge K

focus

entertainment

focus

focus